


Quarterly Report for Q1 2022 released
The Quarterly Report for Q1 2022 was released today and is available here, in Swedish.

Annual Report 2021 released
The Annual Report for 2021 is now available for download from Iconovo´s website. The Annual Report is in Swedish and an English version is yet to be …

Meet Iconovo at RDD, Orlando
A team from Iconovo will visit RDD, Respiratory Drug Delivery in beginning of May, in Orlando. There will be an exhibition from Iconovo with inhalation…

Presentation från Erik Penser Bank Health Care Day
Roger Lassing, VP Business Development på Iconovo, presenterade företaget på Erik Penser Hetlh Care Day den 24 februari 2022 och presentationen…

Iconovo Q4-2021 quarterly report
Significant progress in Iconovo’s three strategic business areas
Significant events 1 October – 31 December
Iconovo signed an agreement…

Covid-19 nasal vaccine ready for clinical studies
Last week, Iconovo’s partner ISR received the reviewed and approved toxicology report that examined the company's vaccine for intranasal…

ICOpre trademarked in Japan
As part of Iconovos global commercialization plan, we are now strengthening our international IP portfolio by trademarking ICOpre in Japan.…

Iconovo establishes Iconovo Pharma AB as a subsidiary for pharmaceutical sales in the Nordic countries
Iconovo AB (publ), that develops complete inhalation products for a global market, has registered the subsidiary Iconovo Pharma AB with the…

How different can a generic inhaler be to the original?
Iconovo has developed ICOpre, a new generic inhaler platform similar to the well-known Ellipta from GSK. ICOpre is available for pharmaceutical…

Iconovo is recruiting as a drive towards increased commercialization
Iconovo is recruiting two new team members to increase the company's commercialization and is now aiming for one to three new signed contracts…

Iconovo and TOA sign agreement for development of a generic product
Iconovo AB (publ), that develops complete inhalation products for a global market, and TOA Pharmaceutical Co., Ltd, which develops generic…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se